Compare Charles River Laboratories Intl. Inc (CRL) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $226.36 (market cap $11.14B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.52. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| CRL | EMLC | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Fixed Income |
52-Week High | $233.60 | $26.59 |
52-Week Low | $145.57 | $24.83 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
EMLC trades at $25.39, down 0.63% over 24 hours, with technical indicators signaling a bearish trend. The ETF maintains a consistent dividend payout, with recent distributions of $0.14 per share. News highlights focus on emerging market debt opportunities amid shifting global volatility, though short interest has risen significantly, indicating investor caution.
Outlook remains mixed; EMLC offers attractive yield above Treasuries but faces currency risk and capital erosion concerns. Key risks include Fed policy shifts and emerging market volatility. Institutional demand is growing, yet high short interest suggests skepticism about sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
